Blog/News

Outside view of a long building with so many displays

Sixty Degree Capital Celebrates Final Close of Fund III, Raising $250M for VC Investment in High-Growth Tech Companies

By Sixty Degree Capital | November 23, 2023

November 23, 2023 – Sixty Degree Capital is excited to announce the final close of its third venture capital fund, with $250M earmarked for high-growth companies from Series A to pre-IPO stages across enterprise software and healthcare. Fund III is…

Read More

T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies

By pwsbuilder | June 22, 2023

– Plan to initiate the IMAG1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in 2021 August 02, 2021 08:00 ET| Source: T-knife Therapeutics SAN FRANCISCO and BERLIN, Aug. 02, 2021 (GLOBE NEWSWIRE) —…

Read More

Everside Health Announces $164 Million in Growth Equity Funding from NEA and New Investors

By pwsbuilder | June 22, 2023

Existing investors NEA, Oak HC/FT and Alta Partners, and new investors, including Endeavor Catalyst, joined the round Funding will accelerate growth, enhance Everside’s technology stack to facilitate predictive, whole-patient care, and support potential M&A opportunities DENVER, July 25, 2022 /PRNewswire/ — Everside Health, LLC, a leading national direct…

Read More

KITE AND ARCELLX ANNOUNCE STRATEGIC COLLABORATION TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA

By pwsbuilder | June 22, 2023

— Collaboration Leverages Expertise Across Both Companies, Including Kite’s Global Cell Therapy Leadership and Industry Leading Reliable Manufacturing — SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced…

Read More

CinCor Pharma to be Acquired by AstraZeneca

By pwsbuilder | June 22, 2023

January 09, 2023 02:05 ET| Source: CinCor Pharma IncFollow WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire…

Read More
Reflexion poster with something written and a girl image

RefleXion Receives FDA Clearance for SCINTIX Biology-Guided Radiotherapy; Cutting-edge Treatment Applicable for Early and Late-stage Cancers

By pwsbuilder | June 22, 2023

HAYWARD, Calif.–(BUSINESS WIRE)–RefleXion Medical, a therapeutic oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted the first marketing clearance for its SCINTIX™ biology-guided radiotherapy, a cutting-edge treatment applicable for early and late-stage cancers. The company will host…

Read More

NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs

By pwsbuilder | June 22, 2023

Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells January 10, 2023 09:00 AM Eastern Standard Time CAMBRIDGE, Mass. & LEVERKUSEN, Germany–(BUSINESS WIRE)–NextPoint Therapeutics, a biotechnology company developing a new world of precision…

Read More
An old lady talking and smiling with a doctor

Strive Health Raises $166 Million in Series C Funding from NEA, CVS Health Ventures and Others

By pwsbuilder | June 22, 2023

AUTHOR : STRIVE HEALTH DENVER — May 31, 2023 — Strive Health, a national leader in value-based kidney care, has raised $166 million in Series C funding. This funding round was led by NEA alongside five new investors, including large strategic investor…

Read More
A Man Standing Beside a Screen With Statistic

Why We Invested in DataGrail

By Alexandre Nossovskoi | October 26, 2022

DataGrail’s approach to first deeply focus on automating data privacy resulted in a robust tech platform that we believe, in the long-term, will outcompete their closest rivals. This platform enables the company to address the burgeoning middle-market, for which competing solutions are weak, and enable it to adapt to future regulation and new opportunities more easily in data privacy and security.

Read More

Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies

By Sixty Degree Capital | October 20, 2021

GAITHERSBURG, Md., April 13, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds…

Read More